Table 9.3	De	sign 2	2
Sequence	Period		
	1	2	3
1	А	В	В
2	В	Α	Α

Table 9.4	De	sign .	3	
Sequence	F	Period		
	1	2	3	
1	А	В	В	
2	В	Α	Α	
3	Α	Α	В	
4	В	В	Α	

can be written in the form

$$y_{ijk} = \mu + \psi_i + s_{(i)k} + \pi_j + \tau_{d(i,j)} + \lambda_{d(i,j-1)} + \epsilon_{ijk}$$
(9.3)

where  $y_{ijk}$  is the response of the kth subject in the *i*th group and *j*th period.  $\psi_i$  is the sequence group effect.  $s_{(i)k}$  is the subject within group or block effect, which can be treated as a fixed or random factor.  $\pi_j$  is the period effect, d(i, j)is the treatment assigned to period *j* for sequence group *i*,  $\tau_l$  is the effect of the *l*th treatment, and  $\lambda_l$  is the first-order carryover effect of the *l*th treatment.

As an example of the use of this model, consider the data in Table 9.5 that comes from a bioequivalence study presented by Chi (1994), where half of the 36 subjects were randomly assigned to the ABB sequence and the other half to the BAA sequence in design 2.

The data in Table 9.5 is available in the data frame **bioequiv** in the R package **daewr**. The variables in this data frame are coded in a way that model 9.3 can be fit. The treatment, d(i, j), given in the *j*th period and the *i*th treatment group, is the variable **Treat** in the data frame. The carryover, d(i, j-1) in the *j*th period and the *i*th treatment group, is the variable **Carry** in the data frame, and its value is the treatment given in the *j*-1st period (if one was given) or none. The remaining variables in the data frame are the group indicator **Group**, the subject indicator **Subject**, and the period indicator **Period**.

The first twelve lines of the data frame **bioequiv** is shown on page 360, and there it can see the carryover indicator is always labeled **none** in the first period. In the second period the carryover indicator is the treatment given in the first period, and in the third period the carryover indicator is the treatment given in the second period.

SIMPLE AB, BA CROSSOVER DESIGNS FOR TWO TREATMENTS 359

Table 9.5Data from Bioequivalence Study Where Subjects in Sequence Group 1 WereGiven ABB and Subjects in Sequence Group 2 Were Given BAA

Group	Subject	Period 1	Period 2	Period 3
1	2	112.25	106.36	88.59
1	3	153.71	150.13	151.31
1	6	278.65	293.27	295.35
1	8	30.25	35.81	34.66
1	10	65.51	52.48	47.48
1	12	35.68	41.79	42.79
1	13	96.03	75.87	82.81
1	14	111.57	115.92	118.14
1	18	72.98	70.69	74.20
1	19	148.98	157.70	178.62
1	21	140.22	119.83	139.48
1	23	60.44	44.09	35.53
1	26	136.10	161.76	163.57
1	28	111.19	101.83	101.70
1	31	85.87	99.60	107.48
1	34	111.25	114.90	135.94
1	36	58.79	96.42	122.60
1	129	299.50	303.45	385.34
2	1	52.66	47.65	13.91
2	4	128.44	173.22	140.44
2	5	233.18	88.18	31.93
2	7	53.87	89.18	70.08
2	9	62.07	54.99	73.39
2	11	183.30	153.88	122.41
2	15	51.91	73.01	23.10
2	16	90.75	89.70	111.94
2	17	59.51	56.26	48.87
2	24	83.01	73.85	71.30
2	25	85.37	86.67	92.06
2	27	84.85	75.41	79.45
2	30	70.33	40.80	46.91
2	32	110.04	102.61	113.18
2	33	93.58	87.31	87.58
2	35	66.54	43.29	84.07
2	120	59.67	56.86	69.49
2	122	49.02	50.29	51.71

>	library(daewr)					
>	data(bioequiv)					
>	head(bioequiv,12)					
	Group	Subject	Period	${\tt Treat}$	Carry	У
1	1	2	1	А	none	112.25
2	1	2	2	В	А	106.36
3	1	2	3	В	В	88.59
4	1	3	1	А	none	153.71
5	1	3	2	В	А	150.13
6	1	3	3	В	В	151.31
7	1	6	1	А	none	278.65
8	1	6	2	В	А	293.27
9	1	6	3	В	В	295.35
10	) 1	8	1	А	none	30.25
11	1	8	2	В	А	35.81
12	2 1	8	3	В	В	34.66

Once the data frame is available, model 9.3 can be fit using the code below. Since the subject indicators within each group are unique, the **Group** term can be left out of the model and the sum of squares for subjects will represent both the random group and subject effects.

```
> modc<-lm(y<sup>Subject+Period+Treat+Carry,data=bioequiv)</sup>
> anova(modc)
Analysis of Variance Table
Response: y
          Df Sum Sq Mean Sq F value Pr(>F)
          35 414306 11837.3 22.5016 <2e-16 ***
Subject
Period
          2
                287
                      143.3 0.2723 0.7624
Treat
           1
               2209 2209.1 4.1993 0.0443 *
Carry
          1
              1051 1050.6 1.9970 0.1622
                     526.1
Residuals 68 35772
___
Signif. codes: 0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1
```

The results show that the treatments are not equivalent (since there is a significant treatment effect at the  $\alpha = 0.05$  significance level), and that the carryover effects are nonsignificant. The **lsmeans** package can be used to get the adjusted means for each treatment level as shown on the next page. The results show that treatment B has a higher average response.

360